Insider · CIK 0001611283
Diane G. Gerst
Files at AMPH (Amphastar Pharmaceuticals, Inc.). First filing -, latest -.
Diane G. Gerst files SEC Form 4 as director at AMPH (Amphastar Pharmaceuticals, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Diane G. Gerst has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Common Stock | +8,143 | $0.00 | $0 | 31,899 | Jun 3, 2026 |
| Jun 1, 2026 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +17,365 | $0.00 | $0 | 17,365 | Jun 3, 2026 |
| Jun 2, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Common Stock | +5,122 | $0.00 | $0 | 23,756 | Jun 4, 2025 |
| Jun 2, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +11,402 | $0.00 | $0 | 11,402 | Jun 4, 2025 |
Questions about Diane G. Gerst
Answered from the filings on this page, as of the latest one.
Is Diane G. Gerst buying or selling?
Diane G. Gerst has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Diane G. Gerst's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Diane G. Gerst has 0.
Where does Diane G. Gerst file Form 4?
Diane G. Gerst has filed Form 4 at AMPH (Amphastar Pharmaceuticals, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.